How PRAC Assesses a Safety Issue During an EMA Referral

Introduction

Once a pharmacovigilance referral has formally started, the regulatory question changes. The issue is no longer simply whether a potential safety signal deserves investigation. PRAC must assess the defined question within the legal and procedural framework of the referral and determine what recommendation, if any, should follow.

This is a scientific assessment performed within a regulatory procedure. It requires integration of evidence from different sources, explicit consideration of uncertainty and a clear connection between the evidence, the benefit-risk balance and the regulatory options available.

The European Medicines Agency describes PRAC as responsible for assessing all aspects of risk management of human medicines, including detection, assessment, minimisation and communication of risks while taking therapeutic effects into account. In safety referrals, PRAC leads the assessment and adopts the pharmacovigilance recommendation that is subsequently considered by CHMP or CMDh as applicable. citeturn0search8turn0search10

The assessment should therefore not be imagined as a simple vote on whether a signal is “real”. It is a structured evaluation of a regulatory question using the available evidence.

A useful conceptual model is:

Formal referral question
        ↓
Definition of scope and assessment framework
        ↓
Evidence collection and validation
        ↓
Rapporteur / co-rapporteur scientific assessment
        ↓
PRAC review and challenge
        ↓
Integrated assessment of risk, benefit and uncertainty
        ↓
Consideration of regulatory options
        ↓
PRAC recommendation

The exact procedure and timetable depend on the legal basis and products concerned. The scientific principles, however, are closely connected across safety referrals.

1. PRAC's Role in a Safety Referral

PRAC is the European Medicines Agency committee responsible for pharmacovigilance and risk assessment. Its remit extends beyond individual referrals to the broader pharmacovigilance system, including safety signals, risk-management plans, post-authorisation safety studies and other risk-management activities. citeturn0search6turn0search8

In a safety referral, PRAC has a specific task: to assess the safety issue within the scope of the procedure and formulate the applicable pharmacovigilance recommendation.

For an Article 20 pharmacovigilance procedure, EMA states that PRAC leads the assessment and that the recommendation is forwarded to CHMP. For an Article 31 pharmacovigilance referral, PRAC likewise leads the assessment, with the recommendation subsequently going to CHMP where centrally authorised products are included or to CMDh where the procedure concerns only nationally authorised products. citeturn0search2turn0search1

This creates an important separation of functions:

PRAC therefore does not simply replace the later regulatory decision-making bodies. Its recommendation is a central scientific component of the referral pathway.

2. The Assessment Starts With the Referral Question

The first discipline in a referral assessment is to understand exactly what has been referred.

A safety issue can be described broadly in pharmacovigilance discussions, but the formal referral establishes a defined regulatory question. That question determines what evidence is relevant and prevents the assessment from becoming an unrestricted review of every aspect of the medicine's safety profile.

For an Article 31 pharmacovigilance referral, EMA explains that the referral notification identifies the safety concern and the question or questions referred to PRAC. PRAC can then identify additional data needed for the assessment. citeturn0search1

The practical sequence is therefore:

Read the question first; build the assessment around the question.

This is one of the most important distinctions between a referral assessment and routine pharmacovigilance signal management.

A referral may ask, for example, whether:

• a suspected adverse reaction is causally associated with the medicine;
• the frequency or severity of an established risk has changed;
• a particular patient population requires additional protection;
• existing risk-minimisation measures remain adequate;
• the benefit-risk balance remains favourable under the current conditions of use; or
• a marketing authorisation should be maintained, varied, restricted or otherwise regulated within the applicable legal framework.

The precise question comes from the procedure. These examples illustrate the types of questions that may need to be answered rather than establishing universal statutory wording.

3. Defining the Scope of the Assessment

Before evidence can be interpreted, PRAC must establish what is within scope.

Scope can involve several dimensions.

Product scope

Which medicinal products and active substances are included?

Safety scope

Which adverse event, adverse-reaction term, syndrome or safety concern is being assessed?

Population scope

Are particular age groups, comorbidities, treatment settings or other populations relevant?

Exposure scope

What exposure periods, doses, formulations or routes of administration are relevant?

Regulatory scope

Which authorised conditions of use and risk-management measures are potentially affected?

This matters because a conclusion can be scientifically correct but still fail to answer the regulatory question if it addresses the wrong population or product group.

For multi-product referrals, the scope may also require comparison of evidence across products and authorisation routes. The assessment must establish whether the evidence supports a common conclusion or whether meaningful differences between products affect the interpretation.

4. Rapporteur and Co-Rapporteur Assessment

PRAC does not normally perform the detailed scientific assessment as an undifferentiated group from the first page of evidence onward.

At the start of an Article 20 pharmacovigilance procedure, the PRAC Chairperson appoints a PRAC rapporteur and co-rapporteur(s) from among PRAC members or alternates. EMA states that the appointments take account of best available expertise, and that existing rapporteur arrangements for centrally authorised products may be relevant. citeturn0search2

The same basic structure applies to Article 31 pharmacovigilance referrals. PRAC rapporteurs and co-rapporteurs perform the assessment of the collected data within the agreed timetable. EMA states that the PRAC Chairperson appoints them from among PRAC members or alternates, with expertise considered in the appointment. citeturn0search1

The rapporteur structure provides a mechanism for detailed scientific analysis before the matter is considered collectively by the committee.

A simplified model is:

Evidence and submissions
        ↓
PRAC rapporteur / co-rapporteur assessment
        ↓
Draft assessment report(s)
        ↓
PRAC member review and comments
        ↓
Scientific discussion within PRAC
        ↓
Adopted recommendation

The rapporteur's conclusion is not automatically the PRAC conclusion. The assessment report is subject to committee scrutiny and discussion.

5. The Assessment Is Evidence-Driven, Not Report-Driven

A referral may begin because a particular signal, study or regulatory event raised concern. PRAC's assessment is broader than the initiating observation.

EMA states that data for pharmacovigilance referrals can be gathered from multiple sources, including MAHs, healthcare professionals, patients' organisations, EudraVigilance and data available to national competent authorities. PRAC can also request additional information during the procedure. citeturn0search1turn0search2

The scientific assessment therefore considers the totality of relevant evidence rather than simply confirming or rejecting the original signal.

Relevant evidence may include:

• individual case safety reports;
• cumulative case-series information;
• EudraVigilance data;
• clinical-trial data;
• epidemiological studies;
• literature;
• exposure estimates;
• utilisation data;
• biological or mechanistic evidence;
• non-clinical evidence where relevant;
• periodic safety information;
• post-authorisation safety-study results;
• risk-management information; and
• information supplied by the MAH or other stakeholders.

The relative importance of each source depends on the question. No universal hierarchy makes one evidence type automatically decisive for every safety issue.

6. Case Reports Are Important, but They Are Not the Whole Assessment

Individual case safety reports can provide the first indication of a safety problem, especially when a previously unrecognised pattern appears.

However, case reports have inherent limitations for causal inference. They may contain incomplete information, reporting biases, confounding, stimulated reporting and uncertainty about exposure or competing causes.

A strong assessment therefore asks what the case reports demonstrate and what they cannot demonstrate.

For example, a cluster of well-documented cases with a consistent temporal relationship may strengthen concern, but the assessment still needs to consider:

• underlying disease;
• concomitant medicines;
• alternative causes;
• exposure duration;
• dechallenge and rechallenge where available;
• biological plausibility;
• expected background incidence; and
• evidence from other sources.

The purpose is not to dismiss case reports because they are observational. It is to place them in the appropriate evidentiary context.

7. Epidemiological Evidence Can Change the Question

When a safety issue can be studied using population-level data, epidemiological evidence may provide information that individual case reports cannot.

For example, an epidemiological study may help assess whether the observed event occurs more frequently among exposed patients than would be expected in an appropriate comparator population.

Interpretation still requires attention to:

• study design;
• exposure definition;
• outcome definition;
• comparator selection;
• confounding;
• bias;
• missing data;
• statistical uncertainty; and
• generalisability to the population relevant to the authorised medicine.

An epidemiological association is not automatically equivalent to causality, just as the absence of a statistically clear association does not automatically exclude a clinically important risk. The interpretation depends on the study's ability to detect the effect of interest and the broader evidence base.

This is why PRAC assessment is an integration exercise rather than a single statistical test.

8. Comparing the New Evidence With the Existing Safety Profile

A referral assessment is usually not performed in a vacuum.

PRAC needs to understand what was already known about the medicine before the referral and what has changed.

The relevant comparison may involve:

• previously recognised adverse reactions;
• known frequencies and severity;
• existing warnings and contraindications;
• known risk factors;
• existing risk-minimisation measures;
• prior regulatory assessments; and
• the previous understanding of the medicine's benefit-risk balance.

This allows the committee to distinguish several different situations:

1. a genuinely new risk;
2. a new aspect of a known risk;
3. an increase in the frequency or severity of a known risk;
4. a risk limited to a particular population or exposure pattern; or
5. evidence that does not materially alter the existing safety profile.

The regulatory significance of these situations can be very different.

9. Benefit Cannot Be Separated From Risk

PRAC's remit is not limited to identifying adverse reactions. EMA states that risk assessment takes therapeutic effects into account. citeturn0search8

This means that the relevant regulatory question is generally not:

“Does the medicine have this risk?”

A medicine can have a real and clinically important risk while retaining a favourable benefit-risk balance.

The more meaningful question is:

“Given the evidence about benefits, risks, uncertainties and available risk-minimisation options, what regulatory position is justified?”

The assessment may therefore need to consider:

• magnitude and seriousness of the benefit;
• magnitude and seriousness of the risk;
• incidence or frequency where it can be estimated;
• affected populations;
• reversibility or preventability;
• treatment alternatives;
• consequences of restricting treatment; and
• whether risk-minimisation can reduce the risk sufficiently.

This is one reason why a referral cannot be understood purely as a signal-validation exercise.

10. Uncertainty Is Part of the Assessment

Safety decisions are often made without perfect evidence.

PRAC may have to interpret evidence that is incomplete, heterogeneous or internally inconsistent. The appropriate response is not to hide the uncertainty but to characterise it.

Important forms of uncertainty can include:

• uncertain exposure denominators;
• incomplete case information;
• limited numbers of events;
• confounding;
• differences between data sources;
• limitations of epidemiological studies;
• uncertain long-term effects;
• uncertainty about specific patient populations; and
• uncertainty about the effectiveness of risk-minimisation measures.

The presence of uncertainty does not automatically prevent regulatory action. Conversely, uncertainty should not automatically be treated as evidence that the risk is large.

A scientifically defensible assessment states what is known, what is reasonably inferred and what remains uncertain.

11. The MAH's Evidence Is Part of the Assessment, Not a Separate Track

The MAH is normally asked to provide information relevant to the safety concern. EMA states that MAHs can submit written or oral explanations within the applicable timetable, and that PRAC may request additional data through questions or outstanding issues. citeturn0search1

The company's submission therefore forms part of the evidence considered by the committee.

This does not mean that the MAH's interpretation determines the outcome.

The scientific task is to evaluate the submitted information alongside evidence available from EMA, national competent authorities and other sources.

EMA's Article 31 guidance also makes clear that responsibility for the quality of the documentation submitted by the MAH rests with the MAH and that submitted data are incorporated into the assessment process. citeturn0search1

For the MAH, this creates two simultaneous obligations:

• provide complete, accurate and scientifically interpretable evidence; and
• distinguish clearly between underlying data and the company's interpretation of those data.

12. What the Rapporteur Assessment Report Does

The rapporteur assessment report is the principal working document through which the detailed scientific analysis is presented to the committee.

EMA states that the PRAC rapporteur assessment report(s) reflect the data submitted and considered for the review and are circulated to PRAC members for comments. For Article 31 pharmacovigilance referrals, the reports are also shared with the relevant CHMP rapporteurs or CMDh member where applicable. citeturn0search1

A good assessment report therefore needs to do more than reproduce the evidence.

It needs to establish a logical chain:

Question
  ↓
Evidence
  ↓
Methodological assessment
  ↓
Interpretation
  ↓
Uncertainty
  ↓
Integrated conclusion
  ↓
Regulatory implication

The assessment should make it possible for committee members to understand not only what the evidence says, but also why the evidence supports the proposed conclusion.

13. PRAC's Assessment Is a Committee Process

The rapporteur assessment is not the end of the scientific process.

The assessment report is circulated to PRAC members, who can comment on the analysis. The committee then considers the evidence and the scientific arguments collectively.

This is important because regulatory scientific assessment involves expert judgement as well as analysis of data.

A rapporteur may identify a particular interpretation, while another PRAC member may identify a limitation, alternative explanation or regulatory implication that needs further consideration.

The resulting recommendation is therefore a committee conclusion, not simply a rapporteur's report reproduced without review.

The committee process also provides a mechanism for addressing divergent scientific views. Where a recommendation is adopted by majority, EMA's procedural material provides for divergent views to be reflected in the recommendation documentation. citeturn0search1

14. From Scientific Assessment to Regulatory Recommendation

The final stage of PRAC assessment is to translate the scientific conclusions into a recommendation within the legal framework of the referral.

Possible regulatory consequences can include maintaining the marketing authorisation, varying it, imposing conditions, strengthening risk-minimisation, or other measures permitted by the applicable procedure. EMA's Article 20 and Article 31 guidance describe the PRAC recommendation as potentially including maintenance or variation of marketing authorisations and conditions on those authorisations. citeturn0search2turn0search1

The important distinction is that the recommendation must be connected to the evidence.

A conclusion such as “the risk is confirmed” is not by itself a complete regulatory recommendation. The committee must consider what that conclusion means for the authorised product and whether a particular regulatory measure is justified.

That transition—from evidence to risk characterisation to regulatory action—is the central function of the PRAC referral assessment.

15. The Assessment Should Answer Three Different Questions

For practical purposes, a referral assessment can be understood as answering three linked questions.

Question 1: What is the evidence?

What information supports or weakens the suspected association?

Question 2: What does the evidence mean?

How strong is the evidence, what causal interpretation is justified, and what uncertainty remains?

Question 3: What should be done?

What regulatory measure is justified by the integrated benefit-risk assessment and the applicable legal framework?

Keeping these questions separate prevents a common analytical error: moving directly from an observed association to a proposed regulatory restriction without explicitly showing the reasoning between them.

The next part of the article will examine that reasoning in greater depth, including how PRAC handles conflicting evidence, causality, risk characterisation, risk-minimisation measures, additional data requests, oral explanations and the formulation of the final recommendation.

14. From Scientific Assessment to Regulatory Recommendation

The final stage of PRAC assessment is to translate the scientific conclusions into a recommendation within the legal framework of the referral.

Possible regulatory consequences can include maintaining the marketing authorisation, varying it, imposing conditions, strengthening risk-minimisation, or other measures permitted by the applicable procedure. The exact options depend on the legal basis, products concerned and evidence available.

The important distinction is between scientific conclusion and regulatory measure.

For example, PRAC may conclude that a particular risk is established or that the existing evidence materially changes the understanding of a risk. That conclusion then has to be translated into an appropriate regulatory response. The scientific conclusion does not itself specify every implementation detail.

A useful model is:

Evidence
   ↓
Scientific conclusion
   ↓
Benefit-risk interpretation
   ↓
Risk-management / regulatory options
   ↓
PRAC recommendation

The recommendation must remain within the scope of the procedure and applicable legislation.

15. Assessing Causality Without Reducing the Question to Causality

Causality is often central to a safety assessment, but a referral is rarely reducible to a single yes-or-no causality question.

The committee may need to determine whether the medicine is associated with an event, how strong the evidence is, which patients are at greatest risk and whether the existing product information adequately reflects that risk.

The evidence may therefore support different degrees of conclusion.

For example:

• the evidence may strongly support a causal relationship;
• the evidence may support an association but leave important uncertainty about causality;
• the evidence may indicate that a previously suspected association is weaker than initially thought; or
• the available evidence may remain insufficient to reach a firm causal conclusion.

These distinctions matter because regulatory action can sometimes be justified by the overall benefit-risk assessment even when scientific uncertainty about a particular causal mechanism remains.

Conversely, a plausible causal hypothesis does not automatically justify a major regulatory restriction. The magnitude of the risk, the affected population, the strength of the evidence, the clinical context and available risk-minimisation options all matter.

16. Evaluating the Frequency and Clinical Importance of a Risk

Establishing that an adverse reaction occurs is only part of understanding its regulatory significance.

PRAC may need to consider the frequency of the event, its severity, preventability, reversibility and clinical consequences.

Frequency can be difficult to estimate accurately for spontaneously reported events because reporting systems generally do not provide a complete denominator of exposed patients.

The assessment may therefore need to integrate different sources of information, such as:

• spontaneous reports;
• clinical-trial exposure;
• observational studies;
• healthcare databases;
• prescription or utilisation information; and
• other relevant epidemiological evidence.

The resulting estimate may still have uncertainty. A scientifically responsible assessment makes that uncertainty explicit rather than presenting an apparently precise number unsupported by the underlying data.

Clinical importance is also not identical to statistical frequency. A rare but severe and preventable event may have a different regulatory significance from a frequent but mild event.

17. Identifying Risk Factors and Populations at Particular Risk

A safety assessment often becomes more useful when it identifies whether the risk is concentrated in particular populations.

Relevant factors can include:

• age;
• renal or hepatic impairment;
• concomitant medicines;
• underlying disease;
• genetic or biological characteristics;
• dose or duration of exposure;
• route of administration; and
• particular clinical circumstances.

The purpose is not simply descriptive. If a risk is concentrated in a definable population, the regulatory options may differ from those for a risk distributed uniformly across all users.

For example, a risk that can be substantially reduced by avoiding treatment in a clearly identifiable high-risk population may lead to a different risk-management consideration from a risk that cannot be predicted or prevented.

This is one reason why PRAC must evaluate the relationship between evidence and practical risk-management possibilities.

18. Considering Existing Risk-Minimisation Measures

A referral does not necessarily begin from the assumption that the existing risk-management system has failed.

PRAC may need to determine whether current measures are adequate in light of the new evidence.

Existing measures can include routine risk-minimisation through product information and, where applicable, additional risk-minimisation measures.

The assessment can therefore ask:

1. Is the risk adequately described?
2. Is the relevant population identifiable?
3. Can prescribers or patients act on the information?
4. Is the proposed behaviour clinically realistic?
5. Is there evidence that existing measures are being implemented effectively?
6. Would additional measures materially reduce the risk?

This assessment requires more than adding another warning to the product information. A warning has value only if it communicates actionable information to the people who need it and if the proposed behaviour can realistically reduce risk.

The effectiveness and feasibility of risk-minimisation are therefore part of the scientific and regulatory reasoning.

19. Additional Questions and Outstanding Issues

The initial evidence package may not answer every question needed for a recommendation.

During the assessment, PRAC can identify gaps and request additional information from the MAH or seek information through the regulatory network. EMA's referral procedures provide for questions and outstanding issues to be addressed during the assessment. citeturn0search1turn0search2

An additional question should be understood as part of the scientific assessment process rather than as evidence that the MAH's original submission was necessarily inadequate.

A committee may request clarification because:

• an analysis needs further explanation;
• a denominator is unclear;
• a subgroup needs additional analysis;
• an alternative explanation needs examination;
• data from different sources appear inconsistent; or
• a potential regulatory consequence requires additional evidence.

For the MAH, the response should answer the question directly, identify the source of the data and explain any limitations rather than simply restating the original position.

20. Oral Explanations and Scientific Dialogue

Where the applicable procedure provides for an oral explanation, it gives the MAH an opportunity to address the committee directly within the procedural framework.

An oral explanation should not be regarded as a substitute for a scientifically complete written submission.

Its value is greatest when it clarifies an important scientific issue, explains a contested interpretation or responds directly to concerns identified during the assessment.

The same evidentiary discipline applies:

• distinguish evidence from interpretation;
• acknowledge limitations;
• answer the committee's question directly; and
• avoid presenting uncertainty as certainty.

The objective is to improve the committee's understanding of the evidence, not to turn the scientific assessment into an adversarial negotiation.

21. How Conflicting Evidence Is Handled

Conflicting evidence is common in pharmacovigilance.

For example, spontaneous reports may indicate a concerning pattern while an epidemiological study does not show a clear association. Clinical-trial data may contain few events, while post-authorisation experience suggests a possible increase. Different studies may produce different estimates.

The appropriate response is not to select whichever source supports the preferred conclusion.

The assessment should examine why the results differ.

Possible explanations include:

• different populations;
• different exposure definitions;
• different outcome definitions;
• different follow-up periods;
• confounding;
• selection bias;
• stimulated reporting;
• insufficient statistical power;
• differences in data quality; or
• genuine heterogeneity of the underlying risk.

The question becomes:

Which interpretation best explains the totality of the evidence, including its limitations?

This is one of the most important areas in which expert scientific judgement is required.

22. Evidence Does Not Have to Be Uniform to Support a Conclusion

A common misconception is that PRAC can reach a conclusion only when every evidence source points in the same direction.

That is not how complex scientific assessment works.

Different evidence types answer different questions and have different strengths and limitations.

A well-designed epidemiological study may provide stronger evidence about relative incidence than spontaneous reports, while individual cases may provide particularly useful information about clinical phenotype, latency or dechallenge.

The committee therefore considers the pattern across evidence sources rather than requiring identical results from every source.

The resulting conclusion should reflect both the direction and strength of the evidence and the remaining uncertainty.

23. The Benefit-Risk Balance Is Reassessed in Context

When a referral concerns a potentially important safety risk, the benefit-risk balance must be reconsidered in the context of the medicine's therapeutic role.

The assessment can include:

This is not a mechanical mathematical calculation applicable to every referral.

Benefit-risk assessment is a structured scientific and regulatory judgement based on the available evidence and the specific therapeutic context.

24. Regulatory Options Considered by PRAC

Once the evidence and benefit-risk implications have been assessed, PRAC considers the regulatory options available under the applicable legal framework.

Depending on the procedure, possible outcomes may include:

• no change to the marketing authorisation;
• changes to product information;
• additional or modified risk-minimisation measures;
• additional pharmacovigilance activities;
• restrictions on use;
• suspension or revocation where the legal framework and evidence support such action; or
• other measures available under the applicable legislation.

The existence of an option does not mean that PRAC will recommend it in every case.

The recommendation should be proportionate to the evidence, the seriousness of the risk, the clinical context and the effectiveness of available alternatives.

25. Proportionality in Regulatory Recommendations

A regulatory recommendation should address the identified problem without imposing unnecessary measures unsupported by the evidence.

This is particularly important where the evidence supports a risk but also indicates that the risk can be controlled through targeted measures.

For example, if a serious risk is confined to a clearly identifiable population and can be prevented by avoiding exposure in that population, the regulatory response may differ from a situation in which the risk is unpredictable and cannot be adequately controlled.

Proportionality does not mean choosing the least restrictive option. It means choosing an option that is justified by the evidence and capable of addressing the regulatory problem.

26. The PRAC Recommendation

At the conclusion of the assessment, PRAC adopts its recommendation according to the applicable referral procedure.

The recommendation reflects the committee's scientific assessment and the regulatory action it considers appropriate within the applicable legal framework.

For Article 20 pharmacovigilance procedures, the PRAC recommendation is subsequently considered by CHMP. For Article 31 pharmacovigilance referrals, the subsequent committee pathway depends on whether centrally authorised medicines are included; CHMP is involved where applicable, while CMDh is relevant for procedures concerning only nationally authorised products. citeturn0search1turn0search2

This is the point at which the PRAC scientific assessment becomes a formal component of the wider regulatory decision-making pathway.

The recommendation should therefore be read carefully for three separate elements:

1. What did PRAC conclude scientifically?
2. What regulatory action did PRAC recommend?
3. What further procedural step follows the recommendation?

These questions should not be collapsed into one.

27. Reading a PRAC Recommendation Correctly

For a pharmacovigilance professional, the most useful reading approach is to move through the recommendation in layers.

First: identify the conclusion

What does PRAC say about the safety concern?

Second: identify the evidence supporting it

Which evidence streams were considered decisive or particularly informative?

Third: identify the remaining uncertainty

What limitations or uncertainties does PRAC acknowledge?

Fourth: identify the regulatory action

What does PRAC recommend changing, maintaining or doing?

Fifth: identify the downstream pathway

Does the recommendation proceed to CHMP, CMDh or another applicable regulatory stage?

This prevents a reader from treating a product-information amendment, for example, as though it were itself the scientific conclusion.

28. What PRAC Assessment Does Not Do

PRAC assessment should not be understood as:

• a simple confirmation or rejection of the original signal;
• an assessment based only on spontaneous reports;
• a vote on the MAH's preferred position;
• a purely statistical exercise;
• a product-information drafting exercise; or
• the final legal decision in every referral.

It is a structured scientific assessment embedded within a legal procedure.

The committee must answer the question referred to it using the evidence available, while recognising uncertainty and identifying the regulatory implications of its conclusion.

29. The QPPV's Perspective on the PRAC Assessment

For the QPPV, understanding the assessment process is important even though the QPPV does not control PRAC's scientific conclusion.

The QPPV should be able to assess whether the company's contribution to the procedure is complete, scientifically coherent and consistent with the company's pharmacovigilance system.

Particular attention should be given to:

• consistency between the referral submission and the company's safety database;
• consistency with previous signal assessments;
• completeness of relevant case information;
• consistency with aggregate safety reports and other safety outputs;
• appropriate consideration of epidemiological evidence;
• clear description of uncertainty;
• appropriate evaluation of existing risk-minimisation measures; and
• traceability of the company's scientific reasoning.

The QPPV should also recognise that a regulator reaching a different scientific conclusion from the MAH does not, by itself, establish a pharmacovigilance-system deficiency.

The critical compliance question remains whether the MAH identified, evaluated, documented and communicated the safety issue appropriately based on the evidence available at the relevant time.

30. Practical Model for Understanding a PRAC Assessment

A useful mental model is:

1. What was the question?
          ↓
2. What evidence exists?
          ↓
3. How reliable is each evidence source?
          ↓
4. What does the evidence mean collectively?
          ↓
5. What remains uncertain?
          ↓
6. What does this mean for benefit-risk?
          ↓
7. Can the risk be adequately managed?
          ↓
8. What regulatory action is justified?
          ↓
9. What does PRAC recommend?

This model is deliberately simpler than the actual committee process. Its purpose is to help a regulatory professional read a referral assessment without confusing evidence, interpretation and regulatory action.

31. What Happens After PRAC?

PRAC's recommendation is not necessarily the final stage of the referral.

The next step depends on the legal basis and the products included in the procedure. Centrally authorised products generally bring CHMP into the subsequent pathway, while nationally authorised products within the relevant procedures can involve CMDh.

The subsequent committee considers the PRAC recommendation within its own legal remit. The European Commission may then adopt the legally operative decision where the applicable procedure requires one.

This distinction is sufficiently important to warrant a separate article. The next article in this series therefore examines what happens after a PRAC recommendation, including the roles of CHMP, CMDh and the European Commission.

Key Takeaways

1. PRAC assesses the defined safety question within the scope of the formal referral.
2. The assessment begins with the referral question, not with an unrestricted review of the entire safety profile.
3. Rapporteurs and co-rapporteurs perform detailed scientific assessment before collective PRAC consideration.
4. PRAC integrates multiple evidence sources rather than relying on a single data stream.
5. Individual case reports are important but have limitations for causal inference.
6. Epidemiological, clinical-trial, literature and other evidence can materially change the interpretation of a signal.
7. New evidence must be interpreted against the medicine's existing safety profile and therapeutic benefits.
8. Uncertainty should be characterised rather than hidden or automatically interpreted as evidence for or against a risk.
9. The MAH's submission is part of the evidence base but does not determine the committee's conclusion.
10. Existing risk-minimisation measures must be considered when determining whether additional action is necessary.
11. Scientific conclusion and regulatory recommendation are related but distinct.
12. PRAC's recommendation forms part of a wider regulatory pathway and is not, in every referral, the final legally operative decision.
13. The QPPV should understand and be able to reconstruct the relationship between the company's pharmacovigilance system, the evidence submitted and the regulatory assessment.

References

1. European Parliament and Council. Regulation (EC) No 726/2004, as amended. EUR-Lex. Legal basis for the centralised system, EMA and the Article 20 pharmacovigilance procedure.
2. European Parliament and Council. Directive 2001/83/EC, as amended. EUR-Lex. Legal framework for medicinal products for human use, including pharmacovigilance referral provisions.
3. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Current EMA information on PRAC's remit and responsibilities.
4. European Medicines Agency. Questions and answers: Article 20 pharmacovigilance procedures. Current procedure-specific guidance concerning PRAC assessment, rapporteurs and the subsequent CHMP pathway.
5. European Medicines Agency. Questions and answers: Article 31 pharmacovigilance referrals. Current procedure-specific guidance concerning PRAC assessment, data requests, rapporteurs and subsequent CHMP/CMDh pathways.
6. European Medicines Agency. Questions and answers: Urgent Union procedures (Article 107i). Current EMA information concerning urgent pharmacovigilance procedures.
7. European Medicines Agency. Referral procedures for human medicines. Current overview of referral procedures and regulatory pathways.
8. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module IX — Signal Management. Current guidance concerning signal detection, validation, analysis, prioritisation and management.
9. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module V — Risk Management Systems. Current guidance concerning risk-management systems and risk-minimisation measures.
10. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VI — Collection, management and submission of reports of suspected adverse reactions. Current guidance relevant to individual case safety reports and their evaluation.

Regulatory Note

This article is an educational explanation of the scientific assessment performed by PRAC during an EU pharmacovigilance referral. It is not a substitute for the applicable legislation, current EMA procedural guidance, GVP, procedure-specific documents or the legally operative outcome of an individual referral.

The precise procedural steps, timetable, documents exchanged and committee pathway depend on the legal basis and products included in the referral. Descriptions in this article are intended to explain the general assessment logic and should not be interpreted as creating universal procedural requirements.

The article deliberately distinguishes scientific evidence, scientific interpretation and regulatory recommendation. A PRAC recommendation should be read together with the underlying assessment documents and the legal framework governing the procedure.

Examples in this article are illustrative and do not represent actual regulatory determinations.

EU legislation and EMA guidance are updated over time. For a live referral, the current consolidated legislation, formal referral notification, applicable timetable, questions referred, assessment reports, adopted committee documents and final legally operative decision should take precedence over this general educational text.

32. Common Misconceptions

PRAC is not simply deciding whether a signal is real

A referral may originate from a signal, but the committee's task is broader. It must assess the evidence relevant to the formal question, characterise uncertainty, consider benefit-risk and determine the regulatory implications.

The rapporteur's assessment is not automatically the PRAC position

The rapporteur and co-rapporteur prepare detailed scientific assessments. Those assessments are circulated for comments and are considered through the committee process. The adopted recommendation is a PRAC conclusion.

A strong case series does not automatically establish the regulatory outcome

Case reports can be highly informative, particularly for recognising a new clinical pattern. They still need to be interpreted in relation to exposure, alternative explanations, background incidence and other evidence.

Statistical uncertainty does not mean that no regulatory action is possible

A safety assessment can remain uncertain while the overall evidence and clinical context justify regulatory action. Conversely, statistical significance alone does not determine the appropriate regulatory measure.

A PRAC recommendation is not necessarily the final legal decision

The subsequent pathway depends on the referral's legal basis and the products involved. CHMP, CMDh and, where applicable, the European Commission have roles after the PRAC recommendation.

Product-information wording is not the same thing as the scientific conclusion

The wording is a regulatory implementation of the assessment. The underlying scientific reasoning should be understood separately from the exact wording selected for the authorised product information.

33. Inspection Considerations for the MAH

A referral is an important test of whether the MAH can demonstrate a coherent pharmacovigilance history.

An inspector may reasonably explore how the company identified and evaluated the issue before the referral, whether relevant information was available internally, how decisions were documented and how the company responded once the procedure began.

The company should be able to reconstruct a defensible chronology:

Information received
      ↓
Case / signal evaluation
      ↓
Safety governance
      ↓
Regulatory escalation
      ↓
Referral initiation
      ↓
Submission and responses
      ↓
Implementation of the outcome

The important inspection principle is contemporaneous traceability. The company should not need to recreate the scientific history retrospectively from scattered documents after the regulator has raised the issue.

Relevant records may include:

• individual case evaluations;
• signal-detection and signal-evaluation records;
• aggregate safety assessments;
• relevant literature evaluations;
• epidemiological analyses;
• safety governance minutes and decisions;
• regulatory correspondence;
• submitted referral responses;
• responses to questions and outstanding issues;
• product-information assessments; and
• implementation records.

The precise records required depend on the issue and the company's pharmacovigilance system.

A changed regulatory conclusion does not automatically demonstrate a historical system failure

A regulator may reach a different conclusion from an MAH because additional evidence became available, because the question was framed differently or because the regulator's integrated assessment weighs evidence differently.

That fact alone does not establish that the MAH's earlier assessment was inadequate.

An inspection should instead examine whether the company fulfilled its applicable pharmacovigilance responsibilities and whether its scientific decisions were reasonable and appropriately documented based on the information available at the relevant time.

34. QPPV Considerations

The QPPV has an important governance perspective on a referral even though PRAC independently performs the regulatory assessment.

The QPPV should be able to establish that the company's referral response is consistent with its broader pharmacovigilance system.

This includes checking, as applicable, whether:

• the referred issue was previously detected or evaluated;
• relevant cases were correctly identified and assessed;
• aggregate safety information is consistent with the referral submission;
• relevant signal-management conclusions are accurately represented;
• important uncertainties have not been omitted;
• risk-management information is consistent with the safety analysis;
• responses to regulatory questions are controlled and traceable; and
• regulatory conclusions are incorporated into the ongoing pharmacovigilance system.

The QPPV should also ensure that scientific disagreement is not converted into organisational defensiveness.

The appropriate objective is to provide the committee with a complete and scientifically transparent evidence base. The purpose of an MAH response is not to make the company's preferred conclusion inevitable.

The QPPV should understand the difference between three statements

“The evidence shows…” refers to the underlying observations or analyses.

“The MAH considers…” identifies the company's scientific interpretation.

“PRAC concluded…” describes the committee's regulatory scientific conclusion.

Keeping these statements separate is particularly important in internal governance and inspection discussions.

35. How to Review a PRAC Assessment Report as an MAH

When the rapporteur assessment report becomes available, a structured review is more useful than reading it only as a response document.

A practical review can proceed through seven questions.

1. What is the committee actually concluding?

Identify the conclusion before drafting the response.

2. Which evidence drives that conclusion?

Determine whether the key evidence is clinical, epidemiological, spontaneous-report based, mechanistic, utilisation-related or a combination.

3. Where does the company disagree?

Separate substantive scientific disagreements from differences in wording or emphasis.

4. Is the disagreement about data or interpretation?

A disagreement about whether a number is correct is different from a disagreement about what that number means.

5. What uncertainty does the assessment identify?

Identify uncertainty that could materially influence the regulatory conclusion.

6. What regulatory consequence follows from the assessment?

Determine how the scientific conclusion is translated into a proposed regulatory measure.

7. What evidence could change the conclusion?

This is often the most useful question when preparing a response to outstanding issues.

The resulting analysis can be organised as:

This table is a working method, not a prescribed EMA format.

36. What Makes a Strong Scientific Response?

A strong response to a PRAC assessment report does not attempt to rebut every sentence.

It identifies the issues that could materially affect the conclusion and addresses them with evidence.

A useful response structure is:

1. state the issue clearly;
2. identify the relevant evidence;
3. explain the methodological point, if one exists;
4. quantify the effect where possible;
5. acknowledge limitations;
6. explain the clinical significance; and
7. state the regulatory implication.

For example, if the company disagrees with an epidemiological conclusion because of residual confounding, simply stating “confounding cannot be excluded” is weak.

A stronger response would explain:

• which confounder is important;
• why it is associated with both exposure and outcome;
• whether it was measured;
• how the study addressed it;
• what residual bias could remain; and
• whether that limitation could materially alter the estimated association.

The response should allow the committee to evaluate the argument rather than requiring it to accept the company's assertion.

37. The Role of New Evidence During the Referral

A referral is not necessarily frozen at the exact evidentiary state that existed on the day it began.

The applicable procedure provides mechanisms for obtaining and considering additional information during the assessment. EMA's Article 31 guidance, for example, describes additional data requests, outstanding issues and further assessment periods where necessary. citeturn0search1

For the MAH, this means that new material information arising during the procedure needs appropriate assessment and escalation through the company's governance system.

The company should avoid two opposite errors:

• treating the initial submission as immutable even when material new evidence becomes available; or
• continuously expanding the response with irrelevant information that does not address the regulatory question.

The correct approach is controlled scientific updating.

38. Public Transparency and the Limits of Public Documents

Some elements of the EU pharmacovigilance process are made public. EMA publishes PRAC recommendations on safety signals and related product-information wording, and publishes other information about the signal-management process. citeturn0search0turn0search5

However, a public recommendation should not automatically be treated as the complete scientific record of the assessment.

For a regulatory professional, the distinction between public communication and the underlying procedural record is important.

A public document may summarise the conclusion while the full scientific reasoning is contained in assessment reports, submissions, questions and responses, committee discussions or other procedural documents.

Therefore, when analysing a historical referral, the primary procedural documents should be consulted rather than relying solely on a short public summary.

39. PRAC Assessment as a Bridge Between Pharmacovigilance and Regulation

The significance of PRAC's role becomes clearer when the referral is viewed as a bridge between two domains.

Pharmacovigilance generates and evaluates evidence about risks.

Regulatory decision-making determines what should happen to the authorised conditions of use in response to that evidence.

PRAC sits at the critical interface between the two.

Pharmacovigilance evidence
          ↓
Scientific evaluation
          ↓
PRAC assessment
          ↓
Benefit-risk interpretation
          ↓
Regulatory recommendation
          ↓
CHMP / CMDh / applicable decision pathway

This is why understanding PRAC requires more than knowing its committee mandate. The professional needs to understand how evidence is transformed into a regulatory recommendation while uncertainty remains visible.

40. A Final Working Framework

When reviewing any PRAC safety referral assessment, ask five questions:

Evidence

What do we actually know?

Interpretation

What does the evidence mean, and what alternative explanations remain?

Uncertainty

What do we still not know, and could it change the conclusion?

Benefit-risk

How does the safety finding alter the balance between therapeutic benefit and risk?

Regulation

What action is justified within the legal framework of the referral?

If those five questions can be answered clearly, the reader can usually understand the logic of the assessment without confusing the underlying data with the regulatory conclusion.

The next article examines what happens after that scientific conclusion: how the PRAC recommendation moves through CHMP or CMDh and, where applicable, to the European Commission and the legally operative regulatory outcome.

Key Takeaways

1. PRAC's assessment is a structured scientific evaluation embedded within a legal procedure.
2. The formal referral question defines the assessment frame.
3. Rapporteurs and co-rapporteurs perform detailed assessment, but the adopted recommendation is a PRAC committee conclusion.
4. The assessment integrates evidence from multiple sources and considers the strengths and limitations of each.
5. Causality is important, but the regulatory question extends beyond a binary causal determination.
6. Frequency, severity, clinical importance, risk factors and preventability all influence regulatory significance.
7. Existing risk-minimisation measures are part of the assessment rather than an afterthought.
8. Conflicting evidence requires explanation and integration, not selective use of favourable results.
9. Uncertainty is explicitly part of sound scientific assessment.
10. The MAH contributes evidence and scientific interpretation but does not control the committee's conclusion.
11. The PRAC recommendation translates the scientific assessment into a regulatory recommendation within the applicable legal framework.
12. The recommendation is not necessarily the final legally operative outcome.
13. For the QPPV, traceability between the pharmacovigilance system, submitted evidence and regulatory response is central.
14. A PRAC assessment should be read as a chain from question → evidence → interpretation → uncertainty → benefit-risk → regulatory action.

References

1. European Parliament and Council. Regulation (EC) No 726/2004, as amended. EUR-Lex. Legal framework for centrally authorised medicinal products, EMA and Article 20 pharmacovigilance procedures.
2. European Parliament and Council. Directive 2001/83/EC, as amended. EUR-Lex. Legal framework for medicinal products for human use and pharmacovigilance referral procedures.
3. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Current EMA information on PRAC's remit and responsibilities.
4. European Medicines Agency. Questions and answers: Article 20 pharmacovigilance procedures. Current procedure-specific information on assessment, rapporteurs and the PRAC recommendation.
5. European Medicines Agency. Questions and answers: Article 31 pharmacovigilance referrals. Current procedure-specific information on PRAC assessment, assessment reports, outstanding issues and oral explanations.
6. European Medicines Agency. Questions and answers: Urgent Union procedures (Article 107i). Current procedure-specific information on PRAC assessment of urgent Union procedures.
7. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), Module IX — Signal Management (Rev. 1). EMA/827661/2011. Scientific and procedural framework for signal management in the EU.
8. European Medicines Agency. GVP Module IX Addendum I — Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions. Methodological guidance for signal detection.
9. European Medicines Agency. GVP Module V — Risk Management Systems. Current guidance on risk-management systems and their integration with pharmacovigilance.
10. European Medicines Agency. GVP Module XVI — Risk Minimisation Measures (Rev. 3). Current guidance on the selection, implementation and evaluation of risk-minimisation measures.
11. European Medicines Agency. Signal management. Current EMA overview of the EU signal-management process and its relationship with referrals and urgent safety restrictions.
12. European Medicines Agency. PRAC recommendations on safety signals. Current public record of adopted PRAC safety-signal recommendations and associated product-information wording.
13. European Medicines Agency. Pharmacovigilance training materials: Safety referrals assessed by PRAC. Educational material describing key stages of safety-referral assessment and assessment-report preparation.

Regulatory Note

This article is an educational explanation of how PRAC assesses a pharmacovigilance safety issue during an EU referral. It is not legal advice and does not replace the applicable legislation, current EMA procedural guidance, Good Pharmacovigilance Practice requirements, procedure-specific documents or the legally operative outcome of an individual procedure.

The precise timetable, documents, opportunities for oral explanation or hearing, committee interactions and downstream regulatory pathway depend on the legal basis and products within the referral. General descriptions in this article should not be treated as additional legal requirements.

The article distinguishes scientific assessment from regulatory decision-making deliberately. PRAC's recommendation is an important scientific and regulatory component of the referral but is not, by itself, necessarily the final legally operative decision.

The scientific assessment may rely on evidence of differing strengths and may contain material uncertainty. The existence of uncertainty does not itself determine whether action is required. Conversely, the existence of a plausible safety concern does not automatically determine the proportional regulatory response.

Examples and working tables in this article are educational tools and do not represent prescribed EMA formats or actual regulatory determinations.

For a live referral, the current consolidated legislation, formal referral notification, applicable timetable, questions referred, assessment reports, MAH submissions and responses, adopted PRAC recommendation, subsequent committee documents and final legally operative decision should take precedence over this general educational text.